Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Research Question:
How well does daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy?

Basic Study Information

Purpose:
This phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with uproleselan may work better in treating patients with acute myeloid leukemia compared to daunorubicin and cytarabine alone.

Location: University of Rochester Medical Center
Study Reference #: CLEU19025

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485
Email: Haley_Misch@URMC.Rochester.edu

Additional Study Details

Return to Search